Purpose. Pertussis remains a public health concern in most countries. Our study aimed to prospectively explore the epidemiology of pertussis in the Tunis area of Tunisia between 2007 and 2016, and to characterize the virulence-associated genes of the collected Bordetella pertussis isolates.
INTRODUCTION
Bordetella pertussis, and to a lesser extent Bordetella parapertussis, are the causative agents of whooping cough, a highly contagious respiratory disease with severe complications in infants and young children [1, 2] . Despite high vaccination coverage, pertussis still occurs in most countries [3] . Recently, Yeung et al. [4] estimated that there were, worldwide, about 24.1 million pertussis cases and 160 700 deaths from pertussis in children younger than 5 years in 2014; the largest proportions of these cases were estimated to occur in the African region.
The reported epidemiology of pertussis varies greatly between regions, due mainly to the use of heterogeneous surveillance programs and different methodologies [5, 6] . Pertussis resurgence, which has been observed in some countries, is likely to be due in part to changes in observation rather than trends in epidemiology [7] . However, this resurgence may also be explained by a decrease in vaccination coverage, immunity waning and pathogen adaptation [1, 7, 8] . Systematic and targeted surveillance of pertussis over a long period is required to monitor the disease epidemiology and to adapt vaccine strategies [5] .
A spread of B. pertussis isolates carrying a particular allele for the pertussis toxin promotor ptxP3 has been reported in Australia, China, many European countries, Japan and the USA [8, 9] since the 1970s. Moreover, circulation of isolates not expressing pertactin (Prn), a key antigenic component of acellular pertussis vaccine (aP), has been observed in the USA [10] [11] [12] , Japan [13, 14] , Canada [15] , Australia [16] and several European countries [17] . Loss of pertactin may provide a selective advantage in populations immunized with the acellular vaccine [18, 19] , as shown in animal models [20] . Studies in France and Australia on pertactindeficient (PrnÀ) isolates detected no significant difference in virulence between PrnÀ and Prn+ isolates [21] , and found no correlation between Prn status and the clinical severity of pertussis infection [22] . To date, there are no prior reports of isolation of B. pertussis in Tunisia, consequently there are few data concerning the genomic evolution and characteristics of circulating strains in this country.
Whole-cell pertussis vaccine (wP) is used in Tunisia, and infants are immunized against pertussis at the age of 2, 3 and 6 months [23] . A booster dose (DTwP) is received at 18 months. The national vaccination coverage level is 95.9 % for the primary 3 doses of pentavalent combined vaccine (DTwP-HepB-Hib), according to the 2013 epidemiology reports. This percentage is lower (86.4 %) for the vaccine booster at 18 months [24] . The pentavalent combined vaccine, manufactured by the Serum Institute of India, has replaced Sanofi Pasteur pertussis vaccine since April 2011; both are wPs.
Pertussis was significantly underreported in Tunisia before 2007, and numbers of cases provided by the Tunisian Ministry of Health were, therefore, likely to be underestimated. Indeed, the diagnosis was only based on clinical criteria and not confirmed using molecular tests. Real-time PCR (qPCR) and culture were introduced for confirmation of pertussis diagnosis at the Children's Hospital of Tunis, Tunisia, in 2007. This allowed evidencing, in a 2007-2011 prospective study, a disease prevalence of 21 % among 599 hospitalized infants aged <1 year with and without pertussoid cough [25] .
Here, we have continued the surveillance efforts and focused on the epidemiology of pertussis in infants and children coming from the Tunis area and hospitalized at the Children's Hospital of Tunis during the period 2007-2016. Furthermore, we characterized some B. pertussis isolates. We thereby provide an update of the epidemiology of pertussis in Tunisia.
METHODS

Patients and samples
The study was conducted at the Children's Hospital of Tunis, which has a bed capacity of 347. It is the only paediatric university teaching hospital in Tunisia. The hospital accepts all children aged less than 18 years, including newborns and infants, residing in the capital city Tunis, but also referred from all over the country. All children hospitalized for respiratory tract infection and suspicion of pertussis from March 2007 to March 2016, and coming from the Tunis area, were enrolled in the present study, without age exclusion criteria. Clinical data were provided from a questionnaire that accompanied specimens. The following variables were recorded by physicians: age, gender, clinical manifestations upon admission (paroxysmal cough, whoops, vomiting, cyanosis and apnoea), antibiotherapy prior to specimen collection and available vaccination status. Samples were collected from patients by physicians and transported to the Laboratory of Microbiology of the Children's Hospital of Tunis. Analysis of specimens was performed by culture and/or qPCR for detection of Bordetella species.
qPCR amplification DNA extraction from clinical samples was carried out using a High Pure PCR template preparation kit (Roche Diagnostics), following the manufacturer's instructions. qPCR was performed to detect the targets IS481, IS1001, recA, H-IS1001 and ptxP as previously described [25] , using a LightCycler 480 II instrument (Roche Diagnostics). Interpretation of amplification curves and cycle threshold (C t ) was performed as described elsewhere [25] . For each positive IS481 result, a second qPCR was performed for the discrimination between B. pertussis and Bordetella holmesii, targeting the promoter region of the pertussis toxin gene (ptxP) of B. pertussis [26] . B. holmesii was detected using primers and probes targeting the recA gene and/or H-IS1001, as described elsewhere [25, 27] .
Genomic DNA from the following reference strains, B. pertussis CIP8132-Tohama, B. parapertussis 12 822 and B. holmesii CIP 104394, were included as controls. They were provided by the French National Reference Center for Whooping Cough and Other Bordetella Infections at Institut Pasteur of Paris.
Bacterial culture and identification
Culture was performed on Bordet-Gengou agar (Difco Laboratories) supplemented with 10 % defibrinated fresh horse blood and 40 mg cephalexin l À1 (Oxoid-Unipath). Inoculated plates were incubated in a moist atmosphere at 36 C, and inspected daily for typical colony growth and morphology. Identification of putative colonies was carried out by classical bacteriological methods, including Gram staining, oxidase testing and the API 20E system (bioM erieux). Suspected Bordetella colonies were also characterized using molecular methods as described above. Confirmed Bordetella isolates were subcultured and stored in BSA/saccharose-phosphate-glutamate (BSA/SPG) solution at À80 C for further investigations.
Characterization of clinical isolates
Antibiotic susceptibility Susceptibility towards erythromycin, azithromycin, clarithromycin and trimethoprim/sulfamethoxazole was tested on Mueller-Hinton medium supplemented with 10 % defibrinated fresh horse blood using the disc diffusion method and interpreted after measurement of the inhibition diameters in agreement with the recommendations of the antibiogram committee of the French Society of Microbiology (CA-SFM) (http://www.sfm-microbiologie.org/UserFiles/ files/casfm/CASFM2013vjuin.pdf).
Serotyping
The detection of fimbrial proteins Fim2 and Fim3 was performed using an agglutination assay with mAbs, as described elsewhere [28] .
Immunoblotting Production of pertussis toxin (PT), pertactin (Prn), filamentous haemagglutinin (FHA) and adenylate cyclase-haemolysin (AC-Hly) by B. pertussis isolates was evidenced by immunoblotting as previously described [29] . Briefly, protein samples were loaded on ready-to-use 4 to 15 % SDS-polyacrylamide gels (Bio-Rad) for electrophoresis (SDS-PAGE). Then, proteins were transferred onto nitrocellulose membranes (Bio-Rad) and incubated with diluted polyclonal sera at 4 C overnight. Horseradish peroxidaselabelled secondary immunoglobulins and SuperSignal West Dura extended duration substrate (ThermoFisher Scientific) were used to visualize antigen-antibody complexes on a chemiluminescence system.
Genotyping
Genotyping of virulence genes encoding pertactin (prn), fimbrial proteins (fim2 and fim3), pertussis toxin promoter (ptxP) and pertussis toxin subunit A (ptxA) was performed using Basic Local Alignment Search Tool (BLAST) [30] with whole-genome sequences obtained from a NextSeq 500 system (Illumina). Alleles were numbered according to international nomenclature [8, 31] .
Statistical analysis
All data were analysed using Epi Info software (version 7.0). Statistical analysis was based on Fisher's exact test and the chi-square test to compare differences in demographic and clinical characteristics between infected and non-infected infants. A statistically significant result was defined by a P value <0.05.
RESULTS
Demographic characteristics of enrolled patients
Patients from the Tunis area hospitalized at the Children's Hospital of Tunis for respiratory tract infection and suspicion of pertussis were enrolled in the present study. Over the 2007-2016 period, a total of 1844 respiratory samples were referred to the Laboratory of Microbiology at the Children's Hospital of Tunis for confirmation of pertussis diagnosis. Among them, 1029 (56 %) were male and the median age was 2 months [interquartile range: 1-3]. Patients' ages ranged from a few days after birth to 10 years. Among the total submitted specimens, 98 % were nasopharyngeal aspirates, whereas 2 % were tracheal samples and bronchial secretions.
Overall, 306 (16.6 %) specimens tested by qPCR were positive for Bordetella species. We estimated an incidence of 134 cases per 100 000 children aged less than 5 years in the Tunis area during the study period. B. pertussis was the most frequent species (265/306; 86.6 %), whereas 5.9 % of positive specimens were infected by B. parapertussis and 12 (3.9 %) samples corresponded to cases of coinfection by both B. pertussis and B. parapertussis. None of the IS481-positive samples was positive for the specific targets of B. holmesii, namely recA and/or H-IS1001 (Table 1) .
Infants with confirmed pertussis had a mean age of 2.6 months ( Table 2 ). The highest proportion of cases (191/ 306; 62 %) occurred in infants younger than 2 months. Infected children had significantly more cough, cyanosis and apnoea, 76 % (n=232), 69 % (n=212) and 24 % (n=72), respectively, compared to those without pertussis infection (P <10
À6
). However, no significant differences were observed for other symptoms, including post-tussive vomiting. Note that 46 % (140/306) of patients positive for Bordetella had started an antibiotic treatment before specimen collection, which may have impacted the sensitivity of pathogen detection.
Phenotypic and genotypic analysis of B. pertussis clinical isolates Given the discontinuous availability of Bordet-Gengou medium, culture was not carried out for the entire study period. Only 799 samples were cultured. From these cultures, 12 B. pertussis isolates were obtained, 10 of which were viable upon subculturing and therefore available for further investigations. The ten patients from which they were isolated were less than 3 months of age and not vaccinated (Table 3) . Among them, nine did not receive antibiotic treatment before specimen collection. Most of them had a history of cyanosis and/or cough without fever. We noticed that isolate recovery was successful only when the C t values of qPCR assays targeting IS481 were below 25. Isolates were first identified by classical bacteriological tools, including oxidase and urease tests, and subsequently identified at the species level by qPCR targeting IS481, IS1001 and ptxP. Susceptibility to antibiotics showed a sensitivity of all B. pertussis isolates to macrolides (inhibition diameter >22 mm) and trimethoprim/sulfamethoxazole (inhibition diameter >16 mm). Serotyping revealed that all isolates expressed the antigen Fim3 and no reaction was observed with anti-Fim2 antibodies. Immunoblotting revealed that they all were producing Prn, PT, FHA and AC-Hly.
Sequence-based typing of ptxP, ptxA, prn, fim2 and fim3 (Table 3) revealed that all Tunisian B. pertussis isolates belonged to the ptxP3 lineage, and harboured ptxA-1 and fim2-1 alleles. Concerning the fim3 alleles, eight isolates were fim3-2 and two were fim3-1. Regarding the pertactin gene, all isolates carried prn2, except one isolate, which had prn3. The most commonly observed (8/10) genotype of Tunisian B. pertussis isolates was ptxP3-ptxA1-prn2-fim2-1-fim3-2.
DISCUSSION
Here, we evaluated the prevalence and characteristics of pertussis among infants and children hospitalized at the Children's Hospital of Tunis between 2007 and 2016. Our results established that pertussis is still circulating in Tunisia, as in other countries with high vaccination coverage. We estimated a population incidence of 134 cases per 100 000 children aged less than 5 years in the Tunis area. Comparatively, B. pertussis was identified in South African children (median age 8 months; interquartile range 4-18) hospitalized with lower respiratory tract infection with an estimated incidence of 526 cases per 100 000 [32] . Other studies revealed an overall pertussis prevalence of 8.2 cases per 1000 children aged <5 years in Niger [33] , whereas in Uganda, pertussis prevalence by PCR was 15 % among 449 participating children [34] . In France, pertussis incidence among infant cases aged 2 months or younger was estimated to be 276 per 100 000 children when an efficacious wP was used [35] .
Our data demonstrated a cyclical pattern of pertussis incidence in Tunisia over the 9 year period, with two noticeable peaks observed in 2009 and in 2014 (respectively 63 and 116 cases). This is in agreement with pertussis cycles occurring every 3 to 5 years, including in populations with high vaccine coverage [35] . Thus, it appears that the circulation of pertussis in Tunisia follows this cyclical pattern, with a higher number of cases registered in 2014 than during the previous peak (Fig. 1) . The observed cyclical nature of pertussis notifications is probably caused by waning of immunity due to natural infections. Interestingly, the increase of the proportion of positive qPCR results preceded the increase in clinical ordering of qPCR testing during the period 2007-2011 (Fig. 1) . However, clinical ordering was more synchronous with positive samples in the period 2012-2016. These observations suggest a better awareness of the medical community towards pertussis infection, possibly explained in part by the information that was provided to them about the improvement of diagnosis tests since the beginning of our surveillance in 2007.
Over the study period, we observed that the proportion of patients with confirmed pertussis younger than 2 months of age, and thus too young to be vaccinated, was considerable (62 %). This has been observed in several other regions of the world and is of particular concern, since complications and deaths occur more frequently in such infants than in older ones [36] . Moreover, cases of pertussis transmission from adolescents or adults to infants have been described in Tunisia and elsewhere [2, 37] . Besides, circulation of pertussis in hospital settings in Tunisia has been recently reported [38] . In fact, adults, particularly parents, represents a potential source of infection for susceptible young infants. This transmission source may be explained by the rapid waning of immunity following pertussis vaccination [1, 39, 40] .
As expected, B. pertussis was the most common pathogen (86.6 %) responsible for pertussis infection in our study. B. parapertussis infection occurred in 5.9 % of cases. This proportion was much higher than in Morocco (0.3 %) [41] and in Algeria, where no B. parapertussis cases were reported [42] . B. holmesii was not detected in any of our IS481-positive samples. This is in contrast with what was observed in Morocco [41] , and the use of the specific targets ptxP and H-IS1001 should, therefore, be continued, in order to avoid misdiagnosis of B. pertussis and B. holmesii infections.
Culture was not performed for the entire study period because of the discontinuous availability of appropriate culture medium. Among 799 inoculated samples, 12 (1.5 %) were positive and only 10 were viable and subcultured for further investigations. Bacterial culture is required to monitor possible antibiotic resistance or failure by the Bordetella isolates to produce a vaccine component [39] . In the present study, the proportion of recovered isolates was low due, probably, to variable delays between specimen collection and culture, and to the low sensitivity of this method [39] . Besides this, prior antibiotic treatment is an obvious cause of failure of pathogen isolation. Clearly, the higher the prevalence of pertussis, the greater the likelihood of obtaining a positive culture. Therefore, our isolates were recovered during the 2014 epidemic period. We believe that culture should be pursued where possible to isolate B. pertussis strains, and advance knowledge on their genotypic and phenotypic characteristics. Currently, efforts are underway to ameliorate culture, systematic notification and diagnosis of pertussis in Tunisia.
All Tunisian isolates produced the surveyed proteins implicated in virulence and antigenicity, namely PT, AC-Hly, FHA, Fim and Prn. The absence of Prn-deficient isolates is consistent with the fact that there has never been a switch from wP to acellular pertussis vaccine in the National Immunization Program of Tunisia. However, more isolates will need to be analysed to monitor the circulation of Prndeficient B. pertussis isolates.
Sequence typing of B. pertussis virulence genes revealed that the most prevalent genotype was ptxP3-ptxA1-prn2-fim2-1-fim3-2. Similar genetic characteristics have been observed in most regions of the world [8, 43] , suggesting that Tunisian B. pertussis isolates are not distinctive. This is consistent with the growth in international exchanges with Tunisia.
B. pertussis can produce either Fim2 or Fim3 or both, depending on the isolates. In Tunisia, B. pertussis isolates expressing Fim3, but not Fim2, were observed, as has also been reported in Algeria [42] , in France [44] and elsewhere [45, 46] . Here, most isolates (7/10) harboured a fim3-2 allele, consistent with current observations in other countries, such as France [8, 44] .
This study provides fresh information about the phenotypic and genetic characteristics of Tunisian B. pertussis isolates. However, some limitations should be considered. First, the number of isolates is quite low. This study reinforces the importance of developing the practice of Bordetella culture and isolation. Second, our results represent only the Tunis area, rather than the country at large. A current challenge for Tunisia is the lack of systematic reporting of pertussispositive cases all over the country, and the fact that diagnosis methods are implemented in only two regions (Tunis and Sfax). Further efforts are required to develop and expand the surveillance of whooping cough in Tunisia, which is needed to inform on the best vaccination strategy.
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